Group 1 - The core viewpoint of the article highlights the significant growth in revenue and net profit for Ascentage Pharma (AAPG), with a total revenue of 981 million RMB, representing a year-on-year increase of 341.77%, and a net profit of -405 million RMB, showing a year-on-year growth of 56.2% as of December 31, 2024 [1][2][3] Group 2 - Ascentage Pharma is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases, and was listed on the Hong Kong Stock Exchange on October 28, 2019 [2] - The company has established a proprietary drug design platform targeting protein-protein interactions and is at the forefront of developing new drugs in the apoptosis pathway, with a pipeline of nine clinical-stage Class 1 small molecule drugs [2] - Ascentage Pharma's core product, Olverembatinib (brand name: Nilotinib), has received priority review and breakthrough therapy designation from the Chinese National Medical Products Administration and is included in the National Basic Medical Insurance Drug List [2] - The company has received multiple orphan drug designations and fast track designations from the FDA for four investigational new drugs, demonstrating its strong research and development capabilities [2] - Ascentage Pharma has established global collaborations with leading biotech and pharmaceutical companies and academic institutions, and is committed to addressing unmet clinical needs for patients worldwide [2]
亚盛医药上涨4.14%，报41.5美元/股，总市值36.15亿美元